1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shionogi & Co., Ltd.

Shionogi & Co., Ltd.

SGIOF
Shionogi & Co., Ltd.US flagOther OTC
17.68
USD
-1.20
- -
15.05BMarket Cap
Shionogi & Co., Ltd.
SGIOF
(Other OTC)

Recent

price

17.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
277.19
281.03
266.03
281.58
288.37
275.01
317.36
349.98
361.67
392.01
359.86
323.26
370.55
477.75
499.9
515.22
238.37
Revenue per Share
38.44
19.93
26.97
66.41
40.43
44.22
68.28
86.62
114.24
146.16
131.9
121.67
126.25
207.1
186.17
200.36
83.25
Basic EPS, GAAP
39.56
45.04
36.24
46.29
72.2
35.09
96.36
104.79
130.02
148.73
132.77
87.95
83.9
185.88
162.69
209.65
107.78
Free Cash Flow per Basic Share
10.65
12.65
13.31
13.31
14.65
16.12
18.65
22.84
25.43
29.45
33.59
35.38
36.65
40.47
50.41
57.25
25.17
Dividend per Share
352.28
359.56
373.2
426.28
448.7
478.54
537.74
546.66
594.74
676.25
787.54
841.41
944.5
1,077.01
1,249.17
1,336.66
1,251.38
Book Value per Share
221.86
227.43
239.38
351.52
393.17
400.03
452.78
449.33
715.22
811.73
761.71
846.97
997.78
1,137.32
1,286.46
1,414.35
1,345.52
Tangible Book Value per Share
1,005
1,005
1,005
1,005
1,005
996
977
968
953
939
926
919
904
893
870
851
858
Basic Weighted Avg Shares
278,502
282,350
267,275
282,903
289,717
273,991
309,973
338,890
344,667
367,960
333,371
297,177
335,138
426,684
435,081
438,268
204,539
Sales/Revenue/Turnover
18.83
16.61
17.59
21.05
21.36
18.38
29.49
31.92
33.43
39.43
39.18
39.52
32.92
34.92
35.24
35.73
26.99
Operating Margin (%)
21,777
22,355
19,707
15,115
15,625
15,650
15,868
16,340
19,007
14,431
14,115
14,779
16,351
17,165
18,323
20,933
9,450
Depreciation Expense
38,625
20,026
27,101
66,727
40,618
44,060
66,687
83,879
108,866
137,191
122,193
111,858
114,185
184,965
162,030
170,435
71,437
Net Income, GAAP
33.99
39.47
34.68
- -
35.56
46.11
31.63
31.85
20.81
21.33
22.91
21.64
10.16
16.26
19.02
15.55
14.88
Effective Tax Rate (%)
13.87
7.09
10.14
23.59
14.02
16.08
21.51
24.75
31.59
37.28
36.65
37.64
34.07
43.35
37.24
38.89
34.93
Profit Margin (%)
183,835
177,118
158,868
168,638
169,885
192,154
243,629
252,789
330,782
397,496
434,907
456,058
534,809
625,640
650,298
729,112
685,005
Working Capital
107,000
93,000
69,000
30,027
10,034
30,094
30,074
30,054
24,124
6,006
4,791
4,608
3,729
6,397
8,753
18,418
8,364
LT Debt
341,976
328,096
347,196
423,632
467,833
478,882
513,876
526,210
734,814
813,087
765,203
864,550
993,285
1,121,878
1,252,561
1,362,496
1,310,799
Total Equity
7.61
6.14
6.83
- -
7.94
5.24
11.47
12.83
13.27
13.86
12.19
10.85
10.33
11.39
10.1
9.83
3.59
Return on Invested Capital (%)
8.66
4.43
5.96
- -
8.34
8.85
12.49
15.02
18.69
22.3
17.91
14.62
13.78
20.22
16.02
15.73
7.15
Return on Capital (%)
11.36
5.6
7.36
16.61
9.24
9.5
13.31
15.91
19.86
22.84
17.91
14.88
14.03
20.37
15.81
15.33
6.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
2,867
- -
3,289
LT Borrowings
- -
- -
- -
LT Finance Leases
8,753
- -
8,364
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
850
- -
851
Market Capitalization
2,191,955
1,809,737
1,871,051

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
784,205
- -
797,909
Cash, Cash Equivalents & STI
573,851
- -
575,921
Accounts Receivable, Net
122,830
- -
131,126
Inventories
64,916
- -
66,120
Total Current Liabilities
133,907
- -
112,904
Payables & Accruals
- -
- -
- -
ST Debt
2,867
- -
3,289
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.54%
12.25%
8.78%
Free Cash Flow
28.95%
17.92%
25.95%
Net Income, GAAP
17.04%
9.68%
5.19%
Sales/Revenue/Turnover
5.34%
6.39%
0.73%
Total Cash Common Dividend
11.89%
9.57%
10.99%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
109,311
121,230
106,278
98,261
435,081
2025
- -
- -
- -
- -
438,268
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48.21
54.69
42.31
- -
186.17
2025
- -
- -
- -
- -
200.36
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25.25
-0.01
25.51
- -
50.41
2025
- -
- -
- -
- -
57.25
2026
- -
- -
- -
- -
- -
Similar Companies
ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
Sandoz Group AG (SDZ.SW)
Xebra Brands Ltd. (XBRA.CN)
Bora Pharmaceuticals Co., Ltd. (6472.TW)
PPD, Inc. (PPD)
Livzon Pharmaceutical Group Inc. (LVZPF)
Business
Shionogi & Co., Ltd. Shionogi & Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals, diagnostic reagents, and medical devices. The company offers a diverse portfolio of prescription drugs targeting infectious diseases including gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, and complicated urinary tract infections; antiviral agents such as baloxavir marboxil; antibacterials like cefiderocol; treatments for chronic pain, neuropathic pain, hyperlipidemia, cancer of the esophagus, bladder, head and neck, and solid tumors; as well as products for allergies including Claritin, cardiovascular diseases, insomnia, acne, dyspareunia, ADHD, Alzheimer's disease, and chronic liver disease with brands such as Naldemedine, lusutrombopag, Osphena, Cymbalta, and adapalene. Shionogi operates primarily in Japan, North America, Europe, and other regions worldwide through more than 20 subsidiaries and maintains sales and supply networks across multiple countries. Founded in 1878 and headquartered in Osaka, Japan, the company focuses on high unmet medical needs in anti-infectives, pain management, and rare diseases. In recent developments, Shionogi completes the acquisition of Japan Tobacco Inc.'s pharmaceutical subsidiaries Torii Pharmaceutical Co., Ltd. and Akros Pharma Inc. for approximately $1.1 billion in 2025, bolstering its global R&D capabilities particularly in AI drug discovery and integrating around 700 employees; it also acquires TORII PHARMACEUTICAL CO., LTD. as a wholly-owned subsidiary in September 2025 and merges with U.S. biotech Qpex Biopharma to extend its infectious disease innovation platform.

Company News

APIChat

  • businesswire.com

    New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure

  • businesswire.com

    Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats

  • businesswire.com

    Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)

  • businesswire.com

    Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

  • seekingalpha.com

    Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript

  • seekingalpha.com

    Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript

  • seekingalpha.com

    Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript

  • seekingalpha.com

    Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript

  • seekingalpha.com

    Shionogi: Likely The Last Viable COVID Play